Introduction {#s1}
============

The incidence of oropharyngeal squamous cell carcinoma (OSCC) is increasing, mainly due to a rise in human papillomavirus (HPV) DNA positive HPV (HPV~DNA~+) OSCC, suggesting an epidemic of viral-induced OSCC\[[@B1]--[@B4]\]. This may be of importance for the treatment of OSCC, where tonsillar squamous cell carcinoma (TSCC) and base of tongue squamous carcinoma (BOTSCC) dominate\[[@B5]\], since HPV~DNA~+ tumors have a much better clinical outcome than those that are HPV DNA negative (HPV~DNA~-)\[[@B6],[@B7]\]. More specifically, patients with HPV~DNA~+ tumors have roughly an 80% 5-year disease-specific survival, compared those with HPV~DNA~- tumors, where survival (40%) is similar to that observed in patients with other head and neck squamous cell carcinomas (HNSCC) of similar stages\[[@B6],[@B8]\].

The fact that most HNSCC patients present with a poor prognosis has resulted in an intensification of the oncological treatment, resulting in a significant increase in acute and late sequele. All patients with HPV~DNA~+ OSCC may not benefit from intensified treatment, and to decrease the severe side-effects, it has been proposed to reduce treatment for this group. However, since a significant proportion of patients with HPV~DNA~+ OSCC have a poor clinical outcome, additional predictive markers are needed, before introducing a possible de-escalation of treatment\[[@B9],[@B10]\].

Extensive data suggest that HPV~DNA~+ OSCC is a different disease-entity from HPV~DNA~- OSCC, and the two should be analyzed separately when searching for additional predictive markers\[[@B11]\]. Furthermore, HPV status can be defined by different methods, e.g. as HPV~DNA~+, or as HPV~DNA~+p16^INK4a^ overexpression or as sometimes by p16^INK4a^ overexpression alone - since p16^INK4^ overexpression is considered a marker of active HPV expressing E7 mRNA\[[@B12]\].

In a previous smaller study, we showed that absent/weak HLA class I expression correlated with a very favorable outcome in HPV~DNA~+ TSCC, while the opposite was observed in HPV~DNA~- TSCC\[[@B13]\]. It is possible that HLA class I downregulation was due to that viral E5 and E7 oncoproteins have the potential to interfere with the HLA class I presenting machinery\[[@B14]--[@B16]\].

In contrast to downregulation of HLA class I expression, HLA class II antigen expression, normally not present in epithelial cells, can be observed in, for instance, cervical cancer\[[@B17]--[@B19]\]. Moreover, *in vitro* HLA class II expression on epithelial cells has been shown to enhance tumor-specific immunity by bypassing the classical antigen-presenting cell-mediated pathway\[[@B20],[@B21]\]. Moreover, HLA class II expression can be linked to both better and worse prognoses in a variety of malignancies, but has not been studied in OSCC\[[@B22]--[@B26]\].

Here, in OSCC, from a large cohort of patients, HLA class I and II expression was analyzed in relation to HPV status and clinical outcome. This extends our previous investigation on the predictive value of HLA class I expression on clinical outcome.

Materials and Methods {#s2}
=====================

Patients, tumor biopsies and treatment {#s2.1}
--------------------------------------

The local cancer registry (\>98% complete) was used to identify patients with OSCC (defined as ICD-10 codes: C09, C01.9, C05.1-8 and C10) diagnosed in the County of Stockholm between January 2000 and October 2009 (C09 and C01.9, for tonsillar and base of tongue cancer respectively) and January 2000 and January 2009 (C05 and C10, for OSCC other than tonsillar and base of tongue cancer). Eligibility criteria were presence of available pathologically verified pre-treatment biopsies and curative treatment with RT. Patient records were then evaluated to verify the diagnosis and to collect patient characteristics ([Table 1](#pone-0077025-t001){ref-type="table"}).

10.1371/journal.pone.0077025.t001

###### Characteristics of patients\* included in the study and their tumors.

                                                                                                                                                                                          **HPV positive OSCC patients (N=303)**   **HPV negative OSCC patients (N=136)**   **All OSCC patients (N=439)**      **p value**                      
  ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------- ---------------------------------------- ---------------------------------------- --------------------------------- --------------- ------- --------- ---------
  **Age**                                                                                                          *Mean (years)*                                                         60                                                                                63                                                61                \<0.001
                                                                                                                   *Median (years)*                                                       59                                                                                62                                                60                
                                                                                                                   *Range (years)*                                                        30-90                                                                             30-87                                             30-90             
                                                                                                                   *Inter-quartile range (years)*                                         53-66                                                                             56-71                                             54-67             
  **Diagnose**                                                                                                     *malignant neoplasm of the base of tongue (C01.9)*    75               25%                                      28                                       21%                               103             24%     \<0.001   
                                                                                                                   *malignant neoplasm of the palate (C05.0-9)*          7                2.3%                                     15                                       11%                               22              5.0%              
                                                                                                                   *malignant neoplasm of the tonsil (C09.0-9)*          217              72%                                      66                                       49%                               283             65%               
                                                                                                                   *malignant neoplasm of the oropharynx (C10.0-9)*      4                1.3%                                     27                                       20%                               31              7.1%              
  **Sex**                                                                                                          *female*                                                               80                                       26%                                      39                                29%             119     27%       0.64
                                                                                                                   *male*                                                                 223                                      74%                                      97                                71%             320     73%       
  **Tumour differentiation**                                                                                       *poor*                                                                 198                                      65%                                      78                                57%             276     63%       0.052
                                                                                                                   *moderate*                                                             89                                       29%                                      45                                33%             134     31%       
                                                                                                                   *well*                                                                 7                                        2.3%                                     10                                7.4%            17      3.9%      
                                                                                                                   *undefined*                                                            9                                        3.0%                                     3                                 2.2%            12      2.7%      
  **Tumour size**                                                                                                  *T1*                                                                   75                                       25%                                      19                                14%             94      21%       0.009
                                                                                                                   *T2*                                                                   110                                      36%                                      43                                32%             153     35%       
                                                                                                                   *T3*                                                                   57                                       19%                                      40                                29%             97      22%       
                                                                                                                   *T4*                                                                   61                                       20%                                      34                                25%             95      22%       
  **Nodal disease**                                                                                                *N0*                                                                   49                                       16%                                      54                                40%             103     23%       \<0.001
                                                                                                                   *N1*                                                                   70                                       23%                                      17                                13%             87      20%       
                                                                                                                   *N2a*                                                                  47                                       16%                                      13                                10%             60      14%       
                                                                                                                   *N2b*                                                                  96                                       32%                                      21                                15%             117     27%       
                                                                                                                   *N2c*                                                                  29                                       10%                                      22                                16%             51      12%       
                                                                                                                   *N3*                                                                   10                                       3.3%                                     8                                 5.9%            18      4.1%      
                                                                                                                   *NX*                                                                   2                                        0.66%                                    1                                 0.74%           3       0.68%     
  **Distant metastasis**                                                                                           *M0*                                                                   297                                      98.0%                                    132                               97%             429     97.7%     0.17
                                                                                                                   *M1*                                                                   3                                        1.0%                                     0                                 0%              3       0.68%     
                                                                                                                   *MX*                                                                   3                                        1.0%                                     4                                 2.9%            7       1.6%      
  **Tumour Stage**                                                                                                 *I*                                                                    4                                        1.3%                                     10                                7.4%            14      3.2%      0.009
                                                                                                                   *II*                                                                   22                                       7.3%                                     14                                10%             36      8.2%      
                                                                                                                   *III*                                                                  76                                       25%                                      33                                24%             109     25%       
                                                                                                                   *IVa*                                                                  183                                      60%                                      68                                50%             251     57%       
                                                                                                                   *IVb*                                                                  15                                       5.0%                                     11                                8.1%            26      5.9%      
                                                                                                                   *IVc*                                                                  3                                        1.0%                                     0                                 0.0%            3       0.68%     
  **Treatment**                                                                                                    *Induction chemotherapy and radiation*                *conventional*   146                                      48%                                      85                                63%             231     53%       0.18
                                                                                                                                                                         *accelerated*    57                                       19%                                      15                                11%             72      16%       
                                                                                                                   *Radiation*                                           *conventional*   28                                       9.2%                                     9                                 6.6%            37      8.4%      
                                                                                                                                                                         *accelerated*    72                                       24%                                      27                                20%             99      23%       
  **Brachytherapy boost**                                                                                          *Not administered*                                                     240                                      79%                                      102                               75.0%           342     78%       0.32
                                                                                                                   *Administered*                                                         63                                       21%                                      34                                25.0%           97      22%       
  **Concomittant Cetuximab**                                                                                       *Not administered*                                                     265                                      87%                                      125                               92%             390     89%       0.19
                                                                                                                   *Administered*                                                         38                                       13%                                      11                                8.1%            49      11%       
  **Smoking**                                                                                                      *Never*                                                                98                                       32%                                      14                                10%             112     26%       \<0.001
                                                                                                                   *Former (\>15 years ago)*                                              54                                       18%                                      7                                 5.1%            61      14%       
                                                                                                                   *Former (\<15 years ago)*                                              52                                       17%                                      13                                10%             65      15%       
                                                                                                                   *Current upon diagnosis*                                               99                                       33%                                      102                               75%             201     46%       
  **p16^INK4a^ expression**                                                                                        *positive*                                                             246                                      81%                                      15                                11%             261     59%       \<0.001
                                                                                                                   *negative*                                                             57                                       19%                                      121                               89%             178     41%       
  \*Number of patients with OSCC according to the local Cancer Registry, and after reviewing patients\' records:   551 patients                                                                                                                                                                                                                 
  Number of patients excluded, not meeting the incusion criteria, due to:                                                                                                                                                                                                                                                                       
                                                                                                                   *Patients without pre-treamtent biopsies available*                                                             45 patients                                                                                                  
                                                                                                                   *Patients with palliative treatment only*                                                                                                                63 patients                                                         
                                                                                                                   *Patients with surgical treatment only*                                                                                                                  4 patients                                                          

Treatment was classified as radiotherapy (RT) (up to 68Gy in a conventional or in an accelerated setting) or induction chemo-RT (CRT) (Cisplatin+5Fu with/without Docetaxel -- or, as in a smaller number of cases, Cisplatin+Docetaxel+Capecitabine -- followed by conventional/accelerated RT). If brachytherapy was added, a total dose up to 78Gy was given. Moreover, some patients also received concomitant Cetuximab treatment ([Table 1](#pone-0077025-t001){ref-type="table"}). Before mid-2007, treatment for patients with regional metastases also included neck dissection. Thereafter, neck dissection was performed only in patients with N2c or N3, and those who had remaining palpable neck nodes after oncological treatment. Smoking data were collected and categorized as: never smoked; stopped \>15 years ago; stopped \<15 years ago and current smoker ([Table 1](#pone-0077025-t001){ref-type="table"}).

A written consent was given by the patients for their information to be stored in the hospital database and to be used for research. The study was conducted according to ethical permissions 2005/431-31/4, 2005/1330-32 and 2009/1278-31/4 from the Regional Ethical Committee at Karolinska Institutet.

HPV DNA analysis {#s2.2}
----------------

DNA was extracted from 30µm paraffin-embedded pre-treatment biopsy slices, as previously described\[[@B2]\]. Presence of HPV DNA was analyzed using a bead-based multiplex assay on a MagPix instrument (Luminex Corporation), as described elsewhere\[[@B27]\].

Immunohistochemistry {#s2.3}
--------------------

HLA class I heavy chains were detected using the mouse monoclonal antibodies (mAb) HCA-2 and HC-10, (HCA-2 recognizes most HLA-A and HC-10 most HLA-B and -C heavy chains, with some overlaps) and HLA class II antigens using mAb LGII-612.14 (recognizes HLA-DR --DQ and DP, but not other HLA class II antigens). These antibodies, kind gifts from Dr Soldano Ferrone, University of Pittsburgh, Cancer Institute, PA, USA, have been extensively described elsewhere\[[@B28]--[@B31]\]. Expression of p16^INK4a^ was detected using the mAb p16^INKA4a^ (clone: JC8, dilution 1:100, Santa Cruz Biotech, California, U.S.A.).

Staining, with negative and positive controls, was performed as previously described\[[@B13]\] and evaluated blind by two investigators (AN and EA). In the case of disagreement a consensus was made. Fractions of HLA class I and II positive cells were evaluated semi-quantitatively as five grades: 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). Staining intensity was also evaluated and scored on a three-tier scale as absent, weak and strong staining\[[@B13]\]. Expression of p16^INK4a^ was scored as positive (strong nuclear staining in \>70% cells) or as negative staining. ([Figure S1](#pone.0077025.s003){ref-type="supplementary-material"} shows examples of staining for HLA class I and p16^INK4a^).

Statistical analysis {#s2.4}
--------------------

The Chi square test was used for categorical data and the student t-test to compare mean values.

Survival was measured in years from the date of diagnosis until a defined event or until 3 years after diagnosis, when patients were censored. An event was defined as death due to any cause (overall survival, OS), death with OSCC present (disease-specific survival, DSS) or recurrence in OSCC (disease-free survival, DFS). Patients who died without a documented OSCC present were considered as a censored observation in DSS and patients who died without a prior recurrence were censored at day 0 in DFS. The Kaplan-Meier estimator was used to estimate DFS, DSS and OS. Differences in survival were tested using the log-rank test. The Cox proportional hazards model was used to calculate the unadjusted and adjusted hazard ratios (HR).

All tests were performed two-sided at the 5% significance level. All calculations were performed using SAS software (ver. 9.3, SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Patients, HPV and tumor characteristics {#s3.1}
---------------------------------------

In total, 551 patients were identified with OSCC, and 439 fulfilled the inclusion criteria e.g. treated with curative intent and with available diagnostic pre-treatment biopsies ([Table 1](#pone-0077025-t001){ref-type="table"}), while 45 patients treated with curative intent without available biopsies were excluded from the analysis ([Table S1](#pone.0077025.s001){ref-type="supplementary-material"}).

Altogether, 303/439 (69%) of the OSCC were HPV~DNA~+, with the majority of HPV~DNA~+ cases being represented by TSCC (217/283, 77%) and BOTSCC (75/103, 73%) respectively. Tumors in the soft palate and oropharynx harbored HPV~DNA~ more rarely - 7/22 (32%) and 4/31 (13%) respectively ([Table 1](#pone-0077025-t001){ref-type="table"}). Overexpression of p16^INK4a^ was significantly more frequently observed in HPV~DNA~+ (p\<0.001) compared to HPV~DNA~- OSCC. However, when analyzed in the different sub-sites separately, significant correlations between HPV~DNA~ and p16^INK4a^ were only observed in TSCC and BOTSCC (both p\<0.001).

Patients with HPV~DNA~+ OSSC, when compared to patients with HPV~DNA~- OSCC, were younger (p\<0.001); more likely never to have smoked (p\<0.001); presented significantly more frequently with smaller tumors (p=0.009); had greater nodal disease (p\<0.001); and had a higher tumor stage (p=0.009) ([Table 1](#pone-0077025-t001){ref-type="table"}).

Treatment modalities were similar for patients with HPV~DNA~+ and HPV~DNA~- OSCC ([Table 1](#pone-0077025-t001){ref-type="table"}).

The 45 patients treated with curative intent who were excluded from the study due to the unavailability of biopsies only differed from the group included in the analysis in terms of treatment, where administration of conventional RT dominated ([Table S1](#pone.0077025.s001){ref-type="supplementary-material"}).

HLA class I and II expression and HPV in OSCC {#s3.2}
---------------------------------------------

In HPV~DNA~+ OSCC, the fraction and intensity of HLA class I expressing cells were generally lower, and the fraction and intensity of HLA class II expressing cells were higher compared to HPV~DNA~- OSCC ([Table 2](#pone-0077025-t002){ref-type="table"}).

10.1371/journal.pone.0077025.t002

###### HLA class I and II exptression in HPV DNA positive and HPV DNA negative oropharyngeal squamous cell carcinoma patients.

                                                            **HPV~DNA~ positive status**   **HPV~DNA~ negative status**               
  --------------------------------------------- ----------- ------------------------------ ------------------------------ ----- ----- ---------
  **Intensity of HCA-2 positive cells**         *absent*    101                            33%                            24    18%   0.001
                                                *weak*      60                             20%                            45    33%   
                                                *strong*    142                            47%                            67    49%   
  **Fraction of HCA-2 positive cells**          *absent*    101                            33%                            24    18%   0.009
                                                *1-25%*     33                             11%                            14    10%   
                                                *26-50%*    24                             8%                             16    12%   
                                                *51-75%*    33                             11%                            14    10%   
                                                *76-100%*   112                            37%                            68    50%   
  **Intensity of HC-10 positive cells**         *absent*    60                             20%                            9     7%    0.001
                                                *weak*      73                             24%                            33    24%   
                                                *strong*    170                            56%                            94    69%   
  **Fraction of HC-10 positive cells**          *absent*    60                             20%                            9     7%    0.001
                                                *1-25%*     24                             8%                             7     5%    
                                                *26-50%*    16                             5%                             4     3%    
                                                *51-75%*    39                             13%                            15    11%   
                                                *76-100%*   164                            54%                            101   74%   
  **Intensity of LGII-612.14 positive cells**   *absent*    100                            33%                            82    60%   \<0.001
                                                *weak*      29                             10%                            11    8%    
                                                *strong*    174                            57%                            43    32%   
  **Fraction of LGII-612.14 positive cells**    *absent*    100                            33%                            82    60%   \<0.001
                                                *1-25%*     26                             9%                             10    7%    
                                                *26-50%*    23                             8%                             7     5%    
                                                *51-75%*    34                             11%                            12    9%    
                                                *76-100%*   120                            40%                            25    18%   

§ Chi-square test

HPV and survival in OSCC patients {#s3.3}
---------------------------------

Patients with HPV~DNA~+ OSCC had a significantly better DFS, DSS and OS than patients with HPV~DNA~- OSCC (p\<0.001 by the log-rank test for all three end-points). The 3-year DFS in the HPV~DNA~+ and the HPV~DNA~- groups was 88% (95% CI 84-91) and 66% (95% CI 56-75) respectively. Corresponding numbers in the two groups for DSS were: 88% (95% CI 84-91) and 59% (95% CI 49-67) respectively; and for OS 84% (95% CI 79-88) and 51% (95% CI 42-59) respectively.

In a multivariate analysis, including sex, age, tumor localization and stage, HPV~DNA~+ status was still a highly significant determinant of survival. The unadjusted hazards ratios for DFS were: 0.30 (95% CI 0.19-0.48); for DSS: 0.23 (95% CI 0.15-0.36) and for OS: 0.26 (95% CI 0.18-0.37) respectively. The corresponding adjusted hazard ratios for DFS were: 0.30 (95% CI 0.18-0.50); for DSS: 0.23 (95% CI 0.15-0.36); and for OS: 0.27 (95% CI 0.18-0.39) respectively.

HLA class I and clinical outcome in patients with HPV~DNA~+ and HPV~DNA~- OSCC {#s3.4}
------------------------------------------------------------------------------

Since HPV~DNA~+ OSCC and HPV~DNA~- OSCC are regarded as two different disease entities, they have been analyzed separately\[[@B2],[@B6]--[@B8],[@B11],[@B13]\].

In HPV~DNA~+ OSCC, absent or a weak HLA class I intensity was in general more often associated with a favorable clinical outcome than strong HLA class I intensity ([Table 3](#pone-0077025-t003){ref-type="table"}). Likewise, if the fraction of positive cells was analyzed, patients with HPV~DNA~+ OSCC with low staining presented a better DFS, DSS and OS than HPV~DNA~+ patients with high staining ([Table 3](#pone-0077025-t003){ref-type="table"}). Only the intensity data are presented in more detail.

10.1371/journal.pone.0077025.t003

###### Univariable and multivariable analyses of HLA class I and II staining with clinical outcome in HPV DNA positive OSCC patients.

                                                                                 DFS                                                                  DSS                                                            OS                                                                                               
  ------------------------------------------------------- ------------- -------- ---------- ---------------- ------------ ---------- ---------------- ----------- ---------- ---------------- ----------- ---------- ---------------- ----------- ---------- ---------------- ----------- ---------- ---------------- -----------
  **HCA-2^[\#](#ngtab3.2){ref-type="table-fn"}^**         *intensity*   strong   1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        weak     0.43       0.17-1.1         0.087        0.42       0.16-1.1         0.082       0.40       0.14-1.2         0.090       0.40       0.14-1.2         0.089       0.50       0.22-1.1         0.097       0.46       0.20-1.1         0.068
                                                                        absent   **0.15**   **0.045-0.50**   **0.0019**   **0.17**   **0.050-0.55**   **0.003**   0.47       0.21-1.0         0.062       0.52       0.23-1.2         0.11        **0.42**   **0.21-0.85**    **0.016**   **0.46**   **0.23-0.94**    **0.033**
                                                          *fraction*    \>76%    1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        51-75%   0.92       0.34-2.5         0.87         1.0        0.38-2.9         0.94        0.70       0.20-2.4         0.58        0.79       0.22-2.8         0.71        0.59       0.21-1.7         0.33        0.67       0.23-2.0         0.47
                                                                        26-50%   1.4        0.50-3.7         0.55         1.4        0.50-3.8         0.55        1.7        0.61-4.7         0.31        1.7        0.60-4.7         0.33        1.3        0.52-3.2         0.58        1.2        0.47-2.9         0.72
                                                                        1-25%    0.59       0.17-2.0         0.39         0.59       0.17-2.0         0.41        1.2        0.44-3.4         0.71        1.2        0.43-3.4         0.73        0.11       0.46-2.5         0.86        1.1        0.46-2.5         0.86
                                                                        absent   **0.18**   **0.052-0.60**   **0.0055**   **0.20**   **0.058-0.68**   **0.010**   0.61       0.25-1.4         0.26        0.68       0.28-1.6         0.38        0.48       0.23-1.0         0.055       0.55       0.26-1.2         0.11
  **HC-10^[\#](#ngtab3.2){ref-type="table-fn"}^**         *intensity*   strong   1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        weak     0.59       0.26-1.4         0.22         0.58       0.25-1.4         0.21        0.71       0.32-1.6         0.39        0.70       0.32-1.6         0.39        0.56       0.27-1.2         0.12        0.52       0.25-1.1         0.083
                                                                        absent              \-               \-                      **-**            **-**       **0.10**   **0.014-0.75**   **0.025**   **0.12**   **0.016-0.91**   **0.040**   **0.22**   **0.066-0.70**   **0.011**   **0.26**   **0.078-0.83**   **0.024**
                                                          *fraction*    \>76%    1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        51-75%   0.70       0.24-2.0         0.52         0.66       0.22-1.9         0.45        0.89       0.34-2.3         0.81        0.83       0.32-2.2         0.71        0.73       0.31-1.8         0.48        0.68       0.28-1.6         0.38
                                                                        26-50%   2.6        0.97-6.8         0.057        2.2        0.85-6.2         0.10        2.5        0.96-6.7         0.062       2.3        0.85-6.2         0.10        1.7        0.68-4.5         0.25        1.4        0.55-3.7         0.47
                                                                        1-25%    0.59       0.14-2.5         0.47         0.54       0.13-2.3         0.41        0.60       0.14-.2.5        0.49        0.55       0.13-2.3         0.42        0.62       0.19-2.0         0.42        0.55       0.17-1.8         0.33
                                                                        absent              \-               \-                      \-               \-          **0.12**   **0.016-0.86**   **0.035**   0.14       0.018-1.0        0.051       **0.24**   **0.073-0.78**   **0.018**   **0.28**   **0.084-0.91**   **0.035**
  **LGII-612.14^[\#](#ngtab3.2){ref-type="table-fn"}^**   *intensity*   strong   1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        weak     0.31       0.041-2.3        0.25         0.39       0.051-2.9        0.32        0.62       0.14-2.7         0.52        0.83       0.19-3.7         0.40        0.73       0.22-2.4         0.086       0.92       0.27-3.1         0.89
                                                                        absent   1.4        0.71-2.9         0.32         1.4        0.71-2.9         0.36        1.3        0.67-2.7         0.41        1.3        0.67-2.7         0.81        1.7        0.93-3.0         0.61        1.6        0.91-2.9         0.099
                                                          *fraction*    \>76%    1.00       (ref)                         1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)                        1.00       (ref)            
                                                                        51-75%   0.83       0.24-2.9         0.77         0.86       0.25-3.0         0.82        2.5        0.76-5.6         0.16        2.1        0.77-5-6         0.15        1.6        0.68-4.0         0.27        1.7        0.68-4.0         0.27
                                                                        26-50%   0.72       0.16-3.2         0.66         0.77       0.17-3.4         0.73        0.46       0.060-3.6        0.46        0.49       0.063-3.8        0.49        0.31       0.042-2.4        0.27        0.32       0.043-2.4        0.27
                                                                        1-25%               \-               \-                      \-               \-          1.3        0.36-4.6         0.71        1.3        0.36-4.6         0.71        0.88       0.26-3.0         0.83        0.83       0.24-2.9         0.77
                                                                        absent   1.3        0.61-2.7         0.50         1.3        0.60-2.7         0.53        1.6        0.73-3.5         0.24        1.6        0.72-3-5         0.26        1.7        0.91-3.3         0.092       1.7        0.87-3.2         0.13

Abbreviations: HPV human papillomavirus; OSCC, oropharyngeal squamous cell carcinoma; DFS, disease-free survival; DSS, disease-specific survival; OS, Overall survival; HR, Hazards ratio ; CI, confidence interval

§ Adjusted for sex, age, tumour stage and tumour localization

\# Antibodies used to detect HLA class I and II

In a Kaplan-Meier analysis, patients with HPV~DNA~+ OSCC with an absence of HLA class I had a better DFS, DSS and OS than those with tumors with strong HLA class I expression. Patients with HPV~DNA~+ OSCC with weak HLA class I expression presented an intermediate survival ([Figure 1](#pone-0077025-g001){ref-type="fig"}).

![Kaplan-Meier curves for disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) in patients with HPV positive oropharyngeal squamous cell carcinoma (OSCC) with known HLA class I expression.\
(A) DFS stratified for HCA-2 intensity, (B) DSS stratified for HCA-2 intensity, (C) OS stratified for HCA-2 intensity, (D) DFS stratified for HC-10 intensity, (E) DSS stratified for HC-10 intensity, and (F) OS stratified for HC-10 intensity. HPV~DNA~+ OSCC with absent HLA class I intensity had a significant better clinical outcome than tumors with strong HLA class I intensity, while weak intensity staining presented an intermediate survival (HCA-2: DFS p\<0.001; DSS p=0.060; OS p=0.022; HC-10: DFS p=0.003, DSS p=0.021 and OS p=0.009, with the log-rank test). Notably, the difference observed in the HCA-2 DSS analysis did not reach significance, although the trend was similar.](pone.0077025.g001){#pone-0077025-g001}

More specifically, the 3-year DFS rates in the groups with absent, weak or strong staining for HCA-2 were 97% (95% CI 90-99); 91% (95% CI 80-96); and 81% (95% CI 73-86) respectively ([Figure 1A](#pone-0077025-g001){ref-type="fig"}). Corresponding numbers for DSS in the three staining categories (absent, weak and strong) were 92% (95% CI 84-96); 93% (95% CI 82-97) and 83% (95% CI 76-89) respectively ([Figure 1B](#pone-0077025-g001){ref-type="fig"}); and for OS 91% (95% CI 83-95); 88% (95% CI 77-94) and 77% (95% CI 70-83) respectively ([Figure 1C](#pone-0077025-g001){ref-type="fig"}).

A similar pattern was obtained for HC-10 staining, with 3-year DFS in the absent, weak and strong staining groups of 100%; 89% (95% CI 79-95); and 83% (95% CI 76-88) respectively ([Figure 1D](#pone-0077025-g001){ref-type="fig"}). Corresponding numbers for DSS in the three staining categories (absent, weak and strong) were 98% (95% CI 89-100); 89% (95% CI 79-94) and 84% (95% CI 77-89) respectively ([Figure 1E](#pone-0077025-g001){ref-type="fig"}), and for OS these were 95% (95% CI 85-98); 88% (95% CI 78-94) and 78% (95% CI 71-84) respectively ([Figure 1F](#pone-0077025-g001){ref-type="fig"}).

In a multivariate analysis, including sex, age, tumor site and stage, absence of HLA class I intensity was still a determinant of favorable clinical outcome in the HPV~DNA~+ group ([Table 3](#pone-0077025-t003){ref-type="table"}). However, this was not the case when analyzing only fractions of positive cells ([Table 3](#pone-0077025-t003){ref-type="table"}).

In the HPV~DNA~- group, the opposite trend was generally observed. The absence of HLA class I staining corresponded to a worse clinical outcome ([Table S2](#pone.0077025.s002){ref-type="supplementary-material"} and [Figure S2](#pone.0077025.s004){ref-type="supplementary-material"}).

HLA class *I*, treatment and clinical outcome in patients with HPV~DNA~+ OSCC {#s3.5}
-----------------------------------------------------------------------------

The possible impact of HLA class I expression on treatment with RT *vs.* CRT was examined, although the two groups were not entirely homogenous since different RT and CRT regimens were used. Furthermore, there was most probably a selection bias for more patients with a poor clinical status receiving only RT than CRT. A Kaplan-Meier analysis was performed for DFS, DSS and OS and presented for DSS in [Figure 2](#pone-0077025-g002){ref-type="fig"}.

![Survival presented with Kaplan-Meier curves, and analyzed using the logrank test, for disease-specific survival (DSS) in patients with HPV-positive oropharyngeal squamous cell carcinoma (HPV~DNA~+ OSCC) with known HLA class I intensity and different treatment regimes.\
(A) DSS in HPV~DNA~+ OSCC with absent HCA-2 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT, (B) DSS in HPV~DNA~+ OSCC with weak HCA-2 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT, (C) DSS in HPV~DNA~+ OSCC with strong HCA-2 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT, (D) DSS in HPV~DNA~+ OSCC with absent HC-10 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT, (E) DSS in HPV~DNA~+ OSCC with weak HC-10 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT, (F) DSS in HPV~DNA~+ OSCC with strong HC-10 intensity stratified for radiotherapy (RT) and induction chemotherapy-RT.](pone.0077025.g002){#pone-0077025-g002}

In HPV~DNA~+ OSCC with absence of HLA class I, there were no significant differences in DFS, DSS ([Figure 2A and 2D](#pone-0077025-g002){ref-type="fig"}) and OS in patients treated with CRT compared to RT: HCA-2: p=0.91, p=0.94 and p= 0.68 respectively; and HC-10: p=1.00, p=0.46 and p=0.20 respectively.

Similarly, there were no differences in DFS, DSS ([Figure 2B and 2E](#pone-0077025-g002){ref-type="fig"}) and OS when the same analysis was performed in HPV~DNA~+ OSCC with weak HLA class I intensity for HCA-2: p=0.15, p=0.88 and p=1.0 respectively; and HC-10: p=0.27, p=0.82 and p=0.99 respectively.

However, patients with HPV~DNA~+ OSCC with strong HLA class I intensity had a significantly better DFS, DSS and OS if treated with CRT than with RT as shown for HCA-2: p=0.030, p=0.007 ([Figure 2C](#pone-0077025-g002){ref-type="fig"}), p=0.002 respectively; and HC-10: p=0.036, p=0.014 ([Figure 2F](#pone-0077025-g002){ref-type="fig"}) and p=0.007 respectively.

HLA class II and clinical outcome in patients with HPV~DNA~+ and HPV~DNA~- OSCC {#s3.6}
-------------------------------------------------------------------------------

HLA class II expression did not influence the clinical outcome in HPV~DNA~+ OSCC ([Table 3](#pone-0077025-t003){ref-type="table"}). In HPV~DNA~- OSCC strong HLA class II staining indicated a better clinical outcome (DFS: p=0.064; DSS: p=0.020; OS: p=0.004) (data not shown and [Table S2](#pone.0077025.s002){ref-type="supplementary-material"}).

p16^INK4a^, HPV~DNA~ status, HLA class I and prognosis {#s3.7}
------------------------------------------------------

Overexpression of p16^INK4a^ correlated to a favorable DFS, DSS and OS irrespective of HPV status (log rank: p\<0.0001 in all endpoints), and in HPV~DNA~+ OSCC (DFS: p=0.055; DSS: p\<0.001; OS: p\<0.001).

In a subgroup analysis, patients with HPV~DNA~+ OSCC with an absence of or weak HLA class I intensity staining generally presented a better clinical outcome than those with OSCC with a strong tumor HLA class I expression, irrespectively of p16^INK4a^ status. More specifically, in HPV~DNA~+ and p16^INK4a^ positive OSCC, absence of or weak HLA class I intensity was an indicator of a favorable DFS ([Figure 3A and C](#pone-0077025-g003){ref-type="fig"}), DSS and OS, as compared to strong HLA intensity staining. However, statistical significance was only obtained for DFS. The generally higher p-values were most likely due to an overall better survival for HPV~DNA~+ p16^INK4a^ positive OSCC with strong HLA class I intensity.

![Survival presented with Kaplan-Meier curves, and analyzed using the logrank test, for disease-free survival (DFS), in patients with HPV-positive (HPV~DNA~+) and p16^INK4a^ positive/negative oropharyngeal squamous cell carcinoma (OSCC).\
(A) DFS in HPV~DNA~+ p16^INK4a^ positive OSCC stratified for HCA-2 intensity (p=0.016), (B) DFS in HPV~DNA~+ p16^INK4a^ negative OSCC stratified for HCA-2 intensity (p=0.072), (C) DFS in HPV~DNA~+ p16^INK4a^ positive OSCC stratified for HC-10 intensity (p=0.024), (D) DFS in HPV~DNA~+ p16^INK4a^ negative OSCC stratified for HC-10 intensity (p=0.083).](pone.0077025.g003){#pone-0077025-g003}

A similar pattern was obtained for HPV~DNA~+ and p16^INK4a^ negative OSCC, with absence of or weak HLA class I tumor intensity staining being an indicator of a favorable DFS ([Figure 3B and D](#pone-0077025-g003){ref-type="fig"}), DSS and OS, as compared to strong HLA intensity staining. However, due to the limited number of patients statistical significance was only obtained for DSS and OS, but not in DFS.

Discussion {#s4}
==========

In this large cohort of OSCC patients, a significant correlation between absent/weak HLA class I expression and a very favorable clinical outcome was observed in HPV~DNA~+ OSCC, independent of treatment regime. In contrast, HPV~DNA~+ OSCC with strong HLA class I intensity presented a worse clinical outcome. HLA class II expression was not correlated to clinical outcome in patients with HPV~DNA~+ OSCC. In HPV~DNA~- OSCC, both a strong HLA class I and a strong class II expression were associated with a better clinical outcome.

The correlation between absent HLA class I expression and favorable clinical outcome in patients with HPV~DNA~+ OSCC was in line with our previous results in TSCC\[[@B13]\], although the underlying mechanism for the favorable outcome is still unknown. Nonetheless, as also stated previously in the pilot study \[[@B13]\], the very suppression of HLA expression may be due to biologically very active HPV in the tumors, where E5 and E7 are known to have the potential to downregulate HLA expression. Such tumors are most likely sensitive to RT, since no additive survival effect was observed between RT and CRT in patients with absent/weak HLA class I staining in HPV~DNA~+ OSCC. However, whether these tumors are truly more sensitive to RT, or perhaps upregulate HLA class I expression during RT, as has been shown in other malignancies\[[@B32],[@B33]\], and are targeted by the immune response, are issues that need further investigation. Other explanations may include immune selection against tumors with strong initial HLA class I expression. Alternatively, these tumors could be more sensitive to NK-cells as has been shown for example for breast cancer or cervical cancer with low HLA expression \[[@B34],[@B35]\].

Patients with HPV~DNA~+ OSCC and strong HLA class I intensity may or may not have benefited from CRT, since we assume that there was a selection bias for patients with a worse clinical condition to receive only RT. Further studies are necessary to clarify the role of CRT for this group.

p16^INK4a^ expression was also evaluated and showed, in line with previous reports\[[@B36]--[@B39]\], correlation to HPV~DNA~ status and favorable clinical outcome. When patients were stratified for HPV status, overexpression of p16^INK4a^ was a prognostic marker in HPV~DNA~+ OSCC. However, whether this correlation is due to our HPV assay sensitivity or to an actual prognostic impact remains to be elucidated.

Interestingly, in HPV~DNA~+ OSCC absence of HLA class I resulted in a very favorable clinical outcome irrespective of p16^INK4a^ overexpression. We suggest that these tumors are indeed caused by HPV, even in those lacking 16^INK4a^ overexpression, since lack of p16^INK4a^ overexpression may be caused by other means than the absence of E7 expression, such as methylation of the 16^INK4a^ promoter\[[@B40]\].

The correlation between strong HLA class I expression and favorable clinical outcome in HPV~DNA~- OSCC is in line with previous studies by others and ourselves in other malignancies, including HNSCC and HPV~DNA~- TSCC, and is often explained by enhanced immune recognition\[[@B13]\].^,^\[[@B41]--[@B43]\]

Upregulated HLA class II expression correlated to a favorable clinical outcome in HPV~DNA~- OSCC similar to what has been shown for some\[[@B22],[@B24]--[@B26]\], but not all malignancies\[[@B23]\]. Furthermore, upregulation of HLA class II antigens did not correlate to absence of/weak expression of HLA class I in HPV~DNA~+ OSCC (data not shown), which could have indicated that absence of HLA class I was compensated for by immune recognition in the context of HLA class II antigens.

The main limitation of this study is the retrospective observational design. Moreover, it is likely that there was a selection bias for patients with a poorer clinical condition to more frequently receive only RT. Nevertheless, our OSCC cohort is one of the largest analyzed, and of the patients treated with the intention to cure \>90% were included. Furthermore, irrespective of treatment with CRT or RT and a possible bias in selection of treatment, patients with HPV~DNA~+ OSCC with an absence of, or weak HLA class I expression presented very high DFS, DSS and OS.

In conclusion, patients with HPV~DNA~+ OSCC and absence of HLA class I had a very high survival, independent of treatment regime. Subsequently, a prospective experimental study should be initiated to better examine absence of HLA class I expression as a marker for de-escalation of oncological treatment.
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